ResMed Stock News

ResMed is rated a buy due to strong fundamentals, expanding margins, robust cash flow, and resilience in recessionary environments. RMD's steady topline growth, high profitability, low debt, and significant cash reserves position it favorably for investors who want to protect their portfolio for a recession. RMD's operational efficiency and cash balance support continued dividend growth and pot...

GLP-1 drugs pose an existential threat to CPAP-makers. ResMed is currently experiencing temporary tailwinds before potential long-term headwinds.

ResMed Inc. ( RMD ) Q1 2026 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Sallilyn Schwartz - Chief Investor Relations Officer Michael Farrell - CEO & Chairman Brett Sandercock - Chief Financial Officer Conference Call Participants Davinthra Thillainathan - Goldman Sachs Group, Inc., Research Division Laura Sutcliffe - Citigroup Inc. Exchange Research Saul Hadassin - Barrenjoe...

Revenue increased by 9% to $1.3 billion; up 8% on a constant currency basis  Gross margin up 290 bps to 61.5%; non-GAAP gross margin up 280 bps to 62.0% Income from operations increased 15%; non-GAAP income from operations up 19% Diluted earnings per share of $2.37; non-GAAP diluted earnings per share of $2.55 Operating cash flow of $457 million Note: A webcast of Resmed's conference call will ...

SAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2026 on Thursday, October 30, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may al...

ResMed Inc. (NYSE:RMD ) Bank of America Global Healthcare Conference 2025 September 23, 2025 8:20 AM EDT Company Participants Michael Farrell - CEO & Chairman Carlos Nunez - Chief Medical Officer Conference Call Participants Lyanne Harrison - BofA Securities, Research Division Presentation Lyanne Harrison BofA Securities, Research Division Good afternoon, everybody. My name is Lyanne Harrison.

SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the Bank of America Global Healthcare Conference 2025 on Tuesday, September 23, 2025, beginning at approximately 1:20 p.m. (British Summer Time) in London.

I track a universe of 50 high-quality dividend growth stocks to identify attractive investment opportunities based on valuation and future return potential. My custom valuation model highlights 23 stocks with estimated future returns above 10%, with 12 of these also appearing undervalued by free cash flow. Top picks include Resmed, MarketAxess, Ferrari, MSCI, Accenture, and others, each offerin...